DONNATAL® TABLETS
Rx Only
Rev. 11/04
DESCRIPTION: Each Donnatal� Tablet contains:
Phenobarbital, USP .................................................16.2 mg
Hyoscyamine Sulfate, USP .......................................0.1037 mg
Atropine Sulfate, USP...............................................0.0194 mg
Scopolamine Hydrobromide, USP ............................0.0065 mg
INACTIVE INGREDIENTS:
Anhydrous Lactose, Calcium Stearate, Colloidal Silicon Dioxide,
Corn Starch, and Microcrystalline Cellulose.
CLINICAL PHARMACOLOGY:
This drug combination provides natural belladonna alkaloids in a
specific, fixed ratio combined with phenobarbital to provide
peripheral anticholinergic/ antispasmodic action and mild sedation.
|
INDICATIONS AND USAGE
Based on a review of this drug by the National Academy of
Sciences-National Research Council and/or other information,
FDA has classified the following indications as ?possibly?
effective:
For use as adjunctive therapy in the treatment of irritable
bowel syndrome (irritable colon, spastic colon, mucous
colitis) and acute enterocolitis.
May also be useful as adjunctive therapy in the treatment of
duodenal ulcer. IT HAS NOT BEEN SHOWN CONCLUSIVELY
WHETHER ANTICHOLINERGIC/ANTISPASMODIC DRUGS
AID IN THE HEALING OF A DUODENAL ULCER, DECREASE
THE RATE OF RECURRENCES OR PREVENT COMPLICATIONS. |
CONTRAINDICATIONS:
Glaucoma, obstructive uropathy (for example, bladder neck
obstruction due to prostatic hypertrophy); obstructive disease of
the gastrointestinal tract (as in achalasia, pyloroduodenal stenosis,
etc.); paralytic ileus, intestinal atony of the elderly or debilitated
patient; unstable cardiovascular status in acute hemorrhage; severe
ulcerative colitis especially if complicated by toxic megacolon;
myasthenia gravis; hiatal hernia associated with reflux esophagitis.
Donnatal� is contraindicated in patients with known hypersensitivity
to any of the ingredients. Phenobarbital is contraindicated in acute
intermittent porphyria and in those patients in whom phenobarbital
produces restlessness and/or excitement.
WARNINGS:
In the presence of a high environmental temperature, heat prostration
can occur with belladonna alkaloids (fever and heatstroke due to
decreased sweating).
Diarrhea may be an early symptom of incomplete intestinal
obstruction, especially in patients with ileostomy or colostomy. In
this instance, treatment with this drug would be inappropriate and
possibly harmful.
Donnatal� may produce drowsiness or blurred vision. The patient
should be warned, should these occur, not to engage in activities
requiring mental alertness, such as operating a motor vehicle or
other machinery, and not to perform hazardous work.
Phenobarbital may decrease the effect of anticoagulants, and
necessitate larger doses of the anticoagulant for optimal effect.
When the phenobarbital is discontinued, the dose of the anticoagulant
may have to be decreased.
Phenobarbital may be habit forming and should not be administered
to individuals known to be addiction prone or to those with a
history of physical and/or psychological dependence upon drugs.
Since barbiturates are metabolized in the liver, they should be
used with caution and initial doses should be small in patients with
hepatic dysfunction.
PRECAUTIONS:
GENERAL
Use with caution in patients with: autonomic neuropathy, hepatic or
renal disease, hyperthyroidism, coronary heart disease, congestive
heart failure, cardiac arrhythmias, tachycardia, and hypertension.
Belladonna alkaloids may produce a delay in gastric emptying
(antral stasis) which would complicate the management of gastric
ulcer.
Do not rely on the use of the drug in the presence of complication
of biliary tract disease.
Theoretically, with overdosage, a curare-like action may occur.
CARCINOGENESIS, MUTAGENESIS, IMPAIRMENT OF FERTILITY:
Long-term studies in animals have not been performed to evaluate
carcinogenic potential.
PREGNANCY
PREGNANCY CATEGORY C
Animal reproduction studies have not been conducted with
Donnatal�. It is not known whether Donnatal� can cause fetal harm
when administered to a pregnant woman or can affect reproduction
capacity. Donnatal� should be given to a pregnant woman only if
clearly needed.
NURSING MOTHERS. It is not known whether this drug is excreted
in human milk. Because many drugs are excreted in human milk,
caution should be exercised when Donnatal� is administered to a
nursing woman.
ADVERSE REACTIONS:
Adverse reactions may include xerostomia; urinary hesitancy and
retention; blurred vision; tachycardia; palpitation; mydriasis; cycloplegia;
increased ocular tension; loss of taste sense; headache;
nervousness; drowsiness; weakness; dizziness; insomnia; nausea;
vomiting; impotence; suppression of lactation; constipation; bloated
feeling; musculoskeletal pain; severe allergic reaction or drug
idiosyncrasies, including anaphylaxis, urticaria and other dermal
manifestations; and decreased sweating. Elderly patients may
react with symptoms of excitement, agitation, drowsiness, and
other untoward manifestations to even small doses of the drug.
Phenobarbital may produce excitement in some patients, rather
than a sedative effect. In patients habituated to barbiturates,
abrupt withdrawal may produce delirium or convulsions.
OVERDOSAGE:
The signs and symptoms of overdose are headache, nausea, vomiting,
blurred vision, dilated pupils, hot and dry skin, dizziness, dryness of
the mouth, difficulty in swallowing, and CNS stimulation. Treatment
should consist of gastric lavage, emetics, and activated charcoal. If
indicated, parenteral cholinergic agents such as physostigmine or
bethanechol chloride, should be used.
DOSAGE AND ADMINISTRATION:
The dosage of Donnatal� should be adjusted to the needs of the
individual patient to assure symptomatic control with a minimum of
adverse effects.
Donnatal� Tablets Adults: One or two Donnatal� tablets three or
four times a day according to condition and severity of symptoms.
HOW SUPPLIED: Donnatal� Tablets are supplied as: White, D-shaped
tablets debossed ?D? on one side and ?Donnatal? on the
other side.
Bottles of 100 tablets NDC 66213-425-10
Bottles of 1000 tablets NDC 66213-425-11
AVOID FREEZING
Store at 20-25�C (68-77�F) [See USP Controlled Room
Temperature].
Protect from light and moisture.
Dispense in a tight, light-resistant container as defined in the USP
using a child-resistant closure. Use safety closures when dispensing
this product unless otherwise directed by a physician or
requested by purchaser.
Also available: Donnatal Extentabs� Tablets, the only extended
release formulation, in bottles of 100 and 500 tablets.
Donnatal� Elixir, a purple colored, grape flavored liquid, in 4 fl oz
(118 mL) and 1 pint (473 mL) bottles.
PBM Pharmaceuticals, Inc.
Gordonsville, VA 22942 |
